Malaria claims some 655,000 lives annually, mostly African children aged under five.38 In 2010, the Gates Foundation funded with $300 million a Phase III trial of GlaxoSmithKline’s experimental malaria vaccine Mosquirix39 in seven African countries, “aimed at young children because their immune system is still developing.”40 GlaxoSmithKline contributed $500 million, NIAID contributed tens of millions in a battery of grants. Lesser funders included USAID, CDC, and Wellcome Trust. Gates is heavily invested in GSK.41 Apparently suspecting the vaccine might be lethal, Gates’s team elected not to
...more